Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.86 Insider Own21.32% Shs Outstand49.35M Perf Week6.52%
Market Cap436.94M Forward P/E- EPS next Y-1.98 Insider Trans-0.21% Shs Float38.98M Perf Month19.19%
Income-78.65M PEG- EPS next Q-0.45 Inst Own71.79% Short Float7.65% Perf Quarter25.46%
Sales0.00M P/S- EPS this Y6.08% Inst Trans2.22% Short Ratio16.64 Perf Half Y12.36%
Book/sh4.22 P/B2.09 EPS next Y-9.18% ROA-35.66% Short Interest2.98M Perf Year-27.65%
Cash/sh4.10 P/C2.15 EPS next 5Y- ROE-40.43% 52W Range5.99 - 12.44 Perf YTD-0.45%
Dividend Est.- P/FCF- EPS past 5Y-16.85% ROI-34.90% 52W High-29.10% Beta0.42
Dividend TTM- Quick Ratio21.97 Sales past 5Y0.00% Gross Margin- 52W Low47.25% ATR (14)0.49
Dividend Ex-Date- Current Ratio21.97 EPS Y/Y TTM6.09% Oper. Margin0.00% RSI (14)65.24 Volatility8.08% 5.97%
Employees89 Debt/Eq0.09 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price19.80
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q13.80% Payout- Rel Volume0.54 Prev Close9.22
Sales Surprise- EPS Surprise17.70% Sales Q/Q- EarningsMay 09 BMO Avg Volume179.24K Price8.82
SMA2016.03% SMA5018.68% SMA2009.93% Trades Volume97,492 Change-4.34%
Date Action Analyst Rating Change Price Target Change
Jul-27-23Initiated Scotiabank Sector Outperform
Apr-17-23Resumed BTIG Research Buy $38
Jul-19-22Initiated JMP Securities Mkt Outperform $26
Jun-06-24 09:55AM
May-30-24 04:05PM
May-23-24 08:00AM
May-10-24 02:58PM
May-09-24 01:55PM
07:00AM Loading…
May-08-24 07:00AM
Mar-27-24 01:53PM
Mar-17-24 05:20PM
Feb-26-24 07:00AM
Dec-11-23 09:55AM
Dec-07-23 08:00AM
Nov-23-23 09:55AM
Nov-09-23 04:05PM
07:00AM Loading…
Nov-08-23 07:00AM
Nov-06-23 10:02PM
Oct-31-23 04:05PM
Oct-02-23 04:05PM
Aug-09-23 07:00AM
Jul-31-23 06:07AM
May-24-23 04:05PM
May-12-23 07:00AM
May-11-23 04:10PM
May-03-23 07:52AM
Mar-15-23 04:10PM
Feb-16-23 10:43AM
07:00AM Loading…
Feb-10-23 06:03AM
Feb-09-23 07:00AM
Dec-24-22 09:27AM
Dec-16-22 09:54AM
Nov-30-22 08:50PM
Nov-24-22 06:34AM
Nov-10-22 07:00AM
Nov-03-22 07:00AM
Oct-06-22 10:12AM
Oct-04-22 07:05AM
Oct-03-22 01:37PM
Sep-28-22 07:00AM
Sep-27-22 07:00AM
Sep-07-22 07:00AM
Sep-01-22 07:00AM
Aug-11-22 04:15PM
Aug-02-22 07:00AM
Jul-19-22 03:04PM
Jul-17-22 08:36AM
Jun-30-22 08:51AM
Jun-23-22 08:44AM
Jun-22-22 04:30PM
Jun-17-22 07:00AM
May-26-22 05:26PM
May-25-22 07:00AM
May-12-22 04:15PM
May-03-22 04:05PM
Apr-29-22 07:53AM
Mar-23-22 04:15PM
Mar-21-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 04:30PM
Feb-28-22 07:00AM
Feb-14-22 05:00PM
Feb-09-22 08:00AM
Feb-03-22 01:38PM
Jan-29-22 07:52AM
Nov-24-21 04:05PM
Nov-23-21 04:05PM
Nov-15-21 11:00AM
Oct-28-21 09:39PM
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de los Pinos ElisabetSee RemarksJan 23 '24Sale7.6415,853121,141161,438Jan 24 04:20 PM
Feder Julie BChief Financial OfficerJan 23 '24Sale7.646,60950,52162,991Jan 24 04:18 PM
Matrix Capital Management Comp10% OwnerNov 09 '23Buy9.001,560,00014,040,0006,922,870Nov 09 04:35 PM
Johnson David MichaelDirectorNov 08 '23Buy7.3020,000146,00075,000Nov 09 05:02 PM
Johnson David MichaelDirectorNov 08 '23Buy7.309,60170,087135,667Nov 09 05:02 PM
Johnson David MichaelDirectorNov 07 '23Buy7.1794,000673,98065,000Nov 09 05:02 PM
Johnson David MichaelDirectorNov 07 '23Buy7.1776,000544,920126,066Nov 09 05:02 PM
Feder Julie BChief Financial OfficerNov 06 '23Option Exercise2.743,90010,68673,500Nov 07 06:09 PM
de los Pinos ElisabetSee RemarksNov 06 '23Option Exercise2.743,80010,412184,740Nov 07 06:19 PM
de los Pinos ElisabetSee RemarksNov 06 '23Sale12.037,44989,611177,291Nov 07 06:19 PM
Feder Julie BChief Financial OfficerNov 06 '23Sale12.073,90047,05469,600Nov 07 06:09 PM
de los Pinos ElisabetSee RemarksOct 30 '23Sale6.839,58665,478180,940Nov 01 06:21 PM
Feder Julie BChief Financial OfficerOct 30 '23Sale6.823,38523,09169,600Nov 01 06:24 PM
Johnson David MichaelDirectorOct 04 '23Buy8.616,56656,51250,066Oct 05 07:56 PM
Johnson David MichaelDirectorOct 03 '23Buy8.2713,500111,66343,500Oct 05 07:56 PM
Last Close
Jul 18 04:00PM ET
Dollar change
Percentage change
ZNTL Zentalis Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-3.36 Insider Own12.49% Shs Outstand70.77M Perf Week-0.75%
Market Cap280.49M Forward P/E- EPS next Y-3.63 Insider Trans-0.47% Shs Float62.14M Perf Month-52.92%
Income-218.90M PEG- EPS next Q-0.84 Inst Own113.63% Short Float15.48% Perf Quarter-68.92%
Sales40.56M P/S6.92 EPS this Y40.00% Inst Trans-0.93% Short Ratio6.77 Perf Half Y-70.63%
Book/sh6.46 P/B0.61 EPS next Y-35.33% ROA-41.82% Short Interest9.62M Perf Year-85.18%
Cash/sh6.89 P/C0.57 EPS next 5Y- ROE-51.86% 52W Range3.27 - 29.03 Perf YTD-73.93%
Dividend Est.- P/FCF- EPS past 5Y-50.05% ROI-43.66% 52W High-86.39% Beta1.71
Dividend TTM- Quick Ratio9.19 Sales past 5Y-20.00% Gross Margin96.66% 52W Low20.80% ATR (14)0.61
Dividend Ex-Date- Current Ratio9.19 EPS Y/Y TTM21.74% Oper. Margin-527.00% RSI (14)31.83 Volatility11.12% 14.99%
Employees168 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin-539.70% Recom2.27 Target Price10.70
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q113.26% Payout- Rel Volume0.57 Prev Close4.29
Sales Surprise170.40% EPS Surprise118.25% Sales Q/Q- EarningsMay 07 BMO Avg Volume1.42M Price3.95
SMA20-5.26% SMA50-53.28% SMA200-68.77% Trades Volume806,937 Change-7.93%
Date Action Analyst Rating Change Price Target Change
Jun-20-24Downgrade UBS Buy → Neutral $28 → $5
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Oct-07-21Resumed Jefferies Buy $120
Jul-01-24 06:00PM
Jun-19-24 10:23AM
Jun-18-24 07:00AM
Jun-03-24 06:00PM
02:43AM Loading…
Jun-01-24 02:43AM
May-30-24 07:00AM
May-29-24 07:00AM
May-23-24 05:01PM
May-14-24 07:00AM
May-08-24 10:27AM
May-07-24 09:04PM
May-01-24 05:30PM
04:05PM Loading…
Apr-02-24 04:05PM
Apr-01-24 05:30PM
Mar-01-24 06:00PM
Feb-28-24 09:55AM
Feb-27-24 07:01PM
Feb-14-24 09:35AM
Feb-13-24 07:00AM
Feb-08-24 12:00PM
Feb-05-24 11:26PM
Feb-01-24 05:00PM
Jan-25-24 07:00AM
Jan-08-24 07:00AM
Jan-02-24 04:49PM
05:39PM Loading…
Dec-01-23 05:39PM
Nov-13-23 09:03PM
Nov-09-23 07:00AM
Nov-06-23 07:13PM
Nov-01-23 04:52PM
Oct-07-23 05:00AM
Oct-02-23 04:27PM
Sep-14-23 01:02AM
Sep-06-23 07:00AM
Sep-01-23 04:37PM
Aug-09-23 07:00AM
Aug-01-23 04:28PM
Jun-15-23 06:01AM
Jun-06-23 06:00AM
Jun-02-23 02:34PM
May-26-23 12:33PM
May-25-23 05:38PM
May-23-23 07:00AM
May-12-23 09:55AM
May-10-23 07:00AM
Apr-26-23 10:00AM
Apr-17-23 09:00AM
Mar-01-23 07:00AM
Feb-13-23 07:00AM
Feb-01-23 05:00PM
Jan-17-23 09:18AM
Jan-03-23 05:00PM
Dec-08-22 09:55AM
Dec-01-22 05:00PM
Nov-09-22 07:00AM
Nov-08-22 07:01AM
Nov-01-22 05:38PM
Oct-24-22 07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:32PM
Sep-27-22 04:01PM
Sep-19-22 07:00AM
Sep-12-22 07:00AM
Sep-01-22 05:00PM
Aug-31-22 07:00AM
Aug-26-22 12:00PM
Aug-16-22 09:55AM
Aug-10-22 04:39PM
Aug-09-22 04:01PM
Aug-03-22 07:00AM
Aug-01-22 05:10PM
Jun-27-22 07:00AM
Jun-14-22 09:10AM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-26-22 09:48AM
May-21-22 09:48AM
May-18-22 04:01PM
May-16-22 07:28AM
May-05-22 07:00AM
Apr-27-22 10:17AM
Apr-19-22 09:35AM
Apr-11-22 04:01PM
Apr-08-22 01:00PM
Mar-29-22 07:00AM
Mar-22-22 07:00AM
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gallagher CamPresident, Interim CFOMay 31 '24Sale11.989,597114,972633,680May 31 06:27 PM
HAUSMAN DIANAChief Medical OfficerMay 09 '24Sale12.623,35642,353373,876May 09 07:46 PM
Epperly Melissa B,Chief Financial OfficerFeb 12 '24Sale11.442,57329,435451,449Feb 12 08:22 PM
Gallagher CamPresidentFeb 12 '24Sale11.441,17313,419643,277Feb 12 08:21 PM
Gallagher CamPresidentFeb 02 '24Sale11.5411,552133,310644,450Feb 05 07:13 PM
Epperly Melissa B,Chief Financial OfficerFeb 02 '24Sale11.548,669100,040454,022Feb 05 07:12 PM
Paul AndreaChief Legal OfficerFeb 02 '24Sale11.543,31038,197149,973Feb 05 07:14 PM
Lackner MarkChief Scientific OfficerFeb 02 '24Sale11.541,58518,291195,728Feb 05 07:15 PM
Blackwell KimberlyChief Executive OfficerNov 13 '23Buy10.295,00051,448254,800Nov 13 05:24 PM
Johnson David MichaelDirectorNov 10 '23Buy9.8817,000167,943144,389Nov 13 05:24 PM
Brownstein CarrieChief Medical OfficerOct 04 '23Sale19.5010,628207,298105,685Oct 06 07:19 PM
Bunker Kevin D.Chief Scientific OfficerOct 04 '23Sale19.506,068118,355859,089Oct 06 07:19 PM
Epperly Melissa B,Chief Financial OfficerOct 04 '23Sale19.505,482106,926387,691Oct 06 07:18 PM
Skvarka JanDirectorSep 11 '23Sale25.055,000125,23847,970Sep 13 04:11 PM